Medication

Search for

Medication research papers

Caffeine consumption and risk of dyskinesia in CALM-PDAuthors examined the association between self-reported intake of the A2A receptor antagonist caffeine and time to dyskinesia in the Comparison of the Agonist Pramipexole with Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) and CALM Cohort extension studies, using a Cox proportional hazards model adjusting for age, baseline Parkinson's severity, site, and initial treatment with pramipexole or levodopa. 15 March 2013
Adenosine A2A receptor antagonist istradefylline reduces daily off time in Parkinson's diseaseAuthors evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double-blind manner in Parkinson's disease patients with motor complications in Japan. 11 March 2013
Rhythm-specific modulation of the sensorimotor network in drug-naïve patients with Parkinson's disease by levodopaThe reported effects induced by levodopa on sensorimotor network topological and spectral features confirm that the sensorimotor system is a target of acute levodopa administration in drug-naïve patients with Parkinson's disease. 01 March 2013
Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysisNocebo refers to adverse events (AEs) generated by patient's negative expectations that medical treatment will likely harm instead of heal and can be assessed in placebo-controlled randomized controlled trials (RCTs). The authors examined AEs following placebo administration in RCTs for Parkinson's disease (PD). 01 March 2013
Dysphagia in Parkinson's disease is responsive to levodopaIn this essay, evidence from published literature and clinical experience is presented, as well as a critical review of the first meta-analysis to explore this issue. The evidence presented supports the traditional view that PD dysphagia is responsive to levodopa. 01 March 2013
RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-conceptHistone deacetylation inhibition may represent a novel approach to reverse established LID in PD and improve quality of the anti-parkinsonian benefit provided by l-DOPA. 01 March 2013
Swallowing improvement after levodopa treatment in idiopathic Parkinson's disease: Lack of evidenceTo date, there is no established effective treatment to restore swallowing function among these subjects. Levodopa is considered the gold standard treatment for motor symptoms in PD but its efficacy in improving oropharyngeal and esophageal dysphagia remains controversial. 01 March 2013
Levodopacarbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim resultsInterim results from this advanced PD cohort demonstrate that LCIG produced meaningful clinical improvements. LCIG was generally well-tolerated; however, device and procedural complications, while generally of mild severity, were common. 01 March 2013
Amantadine improves gait in PD patients with STN stimulationIn conclusion, these data suggest that amantadine may have new beneficial effects on axial symptoms in PD patients with STN-DBS.. 01 March 2013
Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's diseaseResults suggest that STN DBS may reduce compulsive use of dopaminergic medication and its behavioural consequences. Whether this improvement is the result of STN DBS or the consequence of better treatment management remains to be established. 27 February 2013

Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]

[ « Previous | Next » ]